Medical Devices; Immunology and Microbiology Devices; Classification of the Cancer Predisposition Risk Assessment System
Summary
The FDA is officially classifying a new medical test called the Cancer Predisposition Risk Assessment System, which helps doctors identify people who may have a higher genetic risk of developing cancer. This classification sets safety and effectiveness standards for how the test can be marketed and used, helping ensure patients get reliable results to make informed health decisions with their doctors.
Key Points
- 1The FDA is establishing official rules for a genetic test that predicts cancer risk based on a person's DNA
- 2The test is designed to help doctors identify patients who might benefit from early screening or preventive measures
- 3Companies that make or sell this test must now follow FDA standards to prove it works accurately and safely
- 4This classification gives patients and doctors confidence that the test has been reviewed and approved by federal health regulators
- 5Healthcare providers can now use this officially classified test as part of cancer prevention and treatment planning
Impact Assessment
If you are a manufacturer of genetic cancer risk assessment tests, this means you must meet FDA safety and effectiveness standards before marketing your product, which may require additional testing and documentation.
National
Moderate
Key Dates
August 21, 2025
Regulatory Connections
This summary is for informational purposes only. It may not capture all nuances of the regulation. Always refer to the official text for authoritative information.